12-Week open label clinical trial looking at the effects of nicotinamide riboside on bioenergetic metabolism, oxidative stress, and cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease.
NRAD
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Disease.
Alzheimer's disease, Mild cognitive impairment
All genders
55-89
Recruiting now
Overview
Principal Investigator: Brent Forester MD MSc.
Contact Us
Kathryn Turner
Study details
Inclusion Criteria
- - Meet clinical diagnostic criteria for MCI or Mild-AD
- - Study Partner available for duration of the study
- - At least one copy of the APOE e4 allele or AD+ biomarker including Amyloid positive PET scan, tau positive PET scan (MK6240 et al.) or CSF AD biomarkers [i.e., amyloid-beta (AB42), total (T)-tau, and phosphorylated (P)-tau.
Exclusion Criteria
- - Any MRI Contraindication
- - Transient ischemic attack or stroke within the last year
- - Lifetime history of a psychotic disorder
Study Requirements
4 Total Visits (including 1 screening visit) - Blood Draws - MRIs - Cognitive Assessments